Obalon Therapeutics, which is commercializing an intragastric balloon device designed to assist with weight loss, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. Obalon Therapeutics plans to list on the Nasdaq under the symbol OBLN. UBS Investment Bank, Canaccord Genuity and Stifel acted as lead managers on the deal.
